Company Overview
| Stock Name | Consun Pharma |
|---|---|
| Stock Code | 01681 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家在中國主要從事現代中成藥及醫用成像對比劑研究、製造及營銷為一體的藥業公司。 |
| Listing Date | 2013-12-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣州廣州經濟技術開發區東區東鵬大道71號 |
| Business Address (Hong Kong) | 香港德輔道中19號環球大廈22樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.chinaconsun.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 4.36 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.1 / shares |
| Offer Period | 2013-12-12 to 2013-12-12 |
| Global Offering Shares | 250,000,000 shares |
| HK Public Offer Shares (Initial) | 25,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 225,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,000,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 5.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,090,000,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 12.84B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣136.2百萬元 |
| Period-End Cash Balance | 人民幣81.8百萬元 |
| Listing Expenses | ~HK$ 102,500,000 |
| Listing Expenses / Funds Raised | ~9.4% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2010 | 2011 | 2012 | 2013-06 |
|---|---|---|---|---|
| Revenue | 303,713 | 389,305 | 457,801 | 228,390 |
| Cost of sales | -63,728 | -95,507 | -111,112 | -50,023 |
| Gross profit | 239,985 | 293,798 | 346,689 | 178,367 |
| Other income and gains, net | 40,043 | 17,221 | 20,517 | 1,082 |
| Selling and distribution expenses | -127,642 | -116,141 | -135,496 | -73,327 |
| Administrative expenses | -48,989 | -49,368 | -50,721 | -25,421 |
| Operating profit | 103,329 | 145,407 | 179,062 | 80,583 |
| Profit before tax | 103,329 | 145,407 | 179,062 | 80,583 |
| Income tax expense | -24,071 | -38,106 | -42,856 | -21,517 |
| Profit for the year | 79,258 | 107,301 | 136,206 | 59,066 |
| Profit attributable to owners | 79,325 | 107,301 | 136,206 | 59,066 |
Balance Sheet
| Item | 2010 | 2011 | 2012 | 2013-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 32,021 | 64,871 | 81,755 | 200,865 |
| Trade and bills receivables | 204,755 | 230,720 | 264,391 | 244,105 |
| Inventories | 34,921 | 20,360 | 22,442 | 30,766 |
| Total current assets | 271,697 | 315,951 | 445,058 | 484,596 |
| Total assets | 432,213 | 497,021 | 646,007 | 715,466 |
| Total current liabilities | 174,401 | 235,299 | 260,347 | 259,572 |
| Total liabilities | 184,530 | 251,001 | 290,829 | 301,226 |
| Total equity | 247,683 | 246,020 | 355,178 | 414,240 |
| Equity attributable to owners | 247,683 | 246,020 | 355,178 | 414,240 |
| Interest-bearing borrowings | 0 | 13,600 | 0 | 37,000 |
Cash Flow Statement
| Item | 2010 | 2011 | 2012 | 2013-06 |
|---|---|---|---|---|
| Net cash from operating activities | 68,938 | 56,619 | 128,832 | 47,175 |
| Net cash from investing activities | -16,270 | -29,817 | -111,464 | 46,684 |
| Net cash from financing activities | -70,685 | 6,048 | -484 | 25,251 |
| Net increase in cash | -18,017 | 32,850 | 16,884 | 119,110 |
| Purchase of PP&E | -17,689 | -31,629 | -37,334 | -30,514 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 4.9 |
|---|---|
| First Day Open | HK$ 5.0 |
| First Day Change | 12.29% |
| First Day Volume | 189773000.0 |
| First Day Turnover | 931137000.0 |
| Use of Proceeds | 1、約393.5百萬港元(約所得款項凈額總額約40%)將用于我們的基礎設施投資:(i)興建位于廣東省廣州市的新生產基地、倉庫及配套設施,以及購買及安裝該處的生產線;(ii)購買及安裝位于內蒙古自治區通遼市生產基地的新生產設施,(iii)為位于內蒙古自治區通遼市的檢驗中心購買質量控制設備;(iv)為本集團用于生產其他藥品的現有生產線升級;及(v)為本集團的信息系統升級;
2、約196.8百萬港元(約所得款項凈額總額約20%)將用于研發活動,以開發新產品;
3、約147.6百萬港元(約所得款項凈額總額約15%)將用于擴大我們的現有市場推廣及分銷網絡,以增加我們的市場滲透水平至覆蓋更多終端客戶,如縣級醫療機構和小區及農村保健中心,并相應增加我們的市場份額;
4、約147.6百萬港元(約所得款項凈額總額約15%)將用于并購擁有腎病中藥種植能力及該等專注于腎病口服現代中成藥或醫用成像對比劑的企業。我們目前并無任何具體的并購計劃或目標,亦未有與任何潛在目標訂立任何正式協議;
5、約98.4百萬港元(約所得款項凈額總額約10%)將用于營運資金及其他一般企業用途。
|
Underwriting Syndicate
Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (1)
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (1)
中银国际亚洲有限公司 CE AET863
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 景林资产管理有限公司 | 246,885,000 HKD | — | 5.70% | — | 6 months | 2014-06-19 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 安郁寶 | — |
| Company Secretary | 丘志明 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東一致行動集團楊先生、安先生及黎女士合共持股約47.8%;First Kind(由Hony Capital控制)持股22.43%。 |
|---|




